Imatinib mesylate is used in the treatment of blood cancer (chronic myeloid leukaemia), Blood cancer (Acute lymphocytic leukemia) and gastrointestinal stromal tumour. Imatinib mesylate is an anti-cancer medication. A protein enzyme, bcr-abl tyrosine kinase, responsible for the growth of abnormal proliferation of cancer cells. This medicine inhibits the proliferation and induces apoptosis (planned cell death) in bcr-abl positive cells (cancer cells). This is how it works to stop or slow the spread of cancer. Common side effects are edema (swelling), Fatigue, Rash, Fever, Hair loss, Insomnia (difficulty in sleeping), Joint pain, Muscle pain, Weight gain, Night sweats, Itching, Gastrointestinal toxicity, Blood cell abnormalities, Liver toxicity, Renal toxicity, Nasopharyngitis (inflammation of the throat and nasal passages), Upper respiratory tract infection.
